Glucagon transdermal - Zosano Pharma

Drug Profile

Glucagon transdermal - Zosano Pharma

Alternative Names: D107; Glucagon microneedle patch - Zosano Pharma; Glucagon patch - Zosano Pharma; ZP glucagon - Zosano Pharma; ZP-glucagon

Latest Information Update: 23 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Zosano Pharma
  • Class Antihypoglycaemics; Pancreatic hormones
  • Mechanism of Action Glucagon receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Hypoglycaemia

Most Recent Events

  • 29 Mar 2016 Glucagon transdermal - Zosano Pharma is available for licensing in World as of 29 Mar 2016.
  • 29 Mar 2016 Suspended - Phase-II for Hypoglycaemia treatment in Australia (Transdermal)
  • 29 Mar 2016 Zosano Pharma has patent protection for the formulation of glucagon transdermal (Zosano Pharma 10-K; March 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top